The Chart of the Day is Athersys (ATHX). I found the stock by using Barchart to sort today's New High List for frequency in the last month, eliminated the stocks that didn't have a gain in the last week and month and then used the Flipchart feature to review the charts. Since the Trend Spotter signaled a buy on 12/17 the stock soared 194.69%.
is a biopharmaceutical company engaged in the discovery and development
of therapeutic product candidates designed to extend and enhance the
quality of human life. The company's lead product candidate, ATHX-105,
is an oral, selective 5HT2c receptor agonist in Phase I clinical trials
for the treatment of obesity. The company is also developing other
orally active pharmaceutical product candidates for the treatment of
metabolic and central nervous system disorders, utilizing proprietary
technologies, including Random Activation of Gene Expression (RAGE).
Athersys is developing MultiStem(r), its patented, adult-derived ``off
the shelf'' stem cell product platform, for multiple disease
indications, including damage caused by myocardial infarction, bone
marrow transplantation/oncology support, ischemic stroke and other
Please share this article